Therapeutic Advances in Medical Oncology (Mar 2022)

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study

  • Klaus-Peter Dieckmann,
  • Tomas Pokrivcak,
  • Lajos Geczi,
  • David Niehaus,
  • Inken Dralle-Filiz,
  • Cord Matthies,
  • Tamas Dienes,
  • Stefanie Zschäbitz,
  • Pia Paffenholz,
  • Tanja Gschliesser,
  • Renate Pichler,
  • Michal Mego,
  • Pia Bader,
  • Friedemann Zengerling,
  • Julia Heinzelbecker,
  • Philipp Krausewitz,
  • Susanne Krege,
  • Gaetano Aurilio,
  • Cem Aksoy,
  • Marcus Hentrich,
  • Christoph Seidel,
  • Péter Törzsök,
  • Tim Nestler,
  • Matthaeus Majewski,
  • Andreas Hiester,
  • Tomas Buchler,
  • Sonia Vallet,
  • Hana Studentova,
  • Sandra Schönburg,
  • Dora Niedersüß-Beke,
  • Julia Ring,
  • Emanuela Trenti,
  • Axel Heidenreich,
  • Christian Wülfing,
  • Hendrik Isbarn,
  • Uwe Pichlmeier,
  • Martin Pichler

DOI
https://doi.org/10.1177/17588359221086813
Journal volume & issue
Vol. 14

Abstract

Read online

Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to pT2 was significantly associated with relapse rate. Conclusion: The relapse rate of 3.1% found in this population of NS CS1 patients treated with 1xBEP at the routine care level was not inferior to the median rate of 2.3% reported from a meta-analysis of controlled trials. Also, the cure rate of relapses of 77% is consistent with the previously reported rate of 80%. This study clearly shows that the 1xBEP regimen represents a safe treatment for NS CS1 patients.